Related Experiment Videos
Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the
1Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA. salpeter@stanford.edu
Drugs
|October 2, 2009
Summary
Inhaled anticholinergics, particularly tiotropium bromide, effectively reduce hospitalizations and deaths in chronic obstructive pulmonary disease (COPD). New evidence suggests these agents may also decrease cardiovascular events and improve overall survival in COPD patients.
Area of Science:
- Pulmonary Medicine
- Cardiology
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and hospitalization, with cardiovascular disease being the leading cause of hospitalization in COPD patients.
- Shared risk factors (e.g., smoking) and systemic inflammation in COPD contribute to the link between respiratory and cardiovascular diseases.
- Uncertainty exists regarding the cardiovascular risk associated with inhaled anticholinergic agents used in COPD management.
Purpose of the Study:
- To synthesize available data and clarify the controversy surrounding the cardiovascular risk of inhaled anticholinergics (ipratropium bromide and tiotropium bromide) in COPD patients.
- To evaluate the impact of these agents on COPD-related morbidity, mortality, and overall survival.
Main Methods:
- Review and synthesis of available data, including randomized trials and meta-analyses, focusing on cardiovascular events and mortality in COPD patients treated with inhaled anticholinergics.
- Analysis of pooled safety data and incidence rates of cardiovascular events over time.
- Comparison of tiotropium bromide and ipratropium bromide efficacy and safety profiles.
Main Results:
- Inhaled anticholinergics reduce COPD-related hospitalizations and respiratory deaths compared to placebo; tiotropium bromide demonstrates greater efficacy.
- Conflicting meta-analyses exist regarding cardiovascular risk, but recent analyses including new trial data show no increased risk.
- Pooled safety analysis indicates tiotropium bromide is associated with a lower rate of major cardiovascular events and deaths, particularly myocardial infarction and congestive heart failure, when evaluated per person-years of exposure.
Conclusions:
- Inhaled anticholinergics, especially tiotropium bromide, are effective in reducing COPD-related morbidity and mortality, potentially improving overall survival.
- The apparent higher incidence of cardiovascular events in trials may be due to the high prevalence of cardiovascular disease in COPD patients and is mitigated when analyzed per person-years.
- Emerging evidence suggests tiotropium bromide may offer a protective effect against cardiovascular events and deaths in COPD patients, possibly through improved respiratory status.
Related Concept Videos
01:28Cholinergic Antagonists: Pharmacological Actions
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
01:26Cholinergic Antagonists: Therapeutic Uses
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
01:24Cholinergic Antagonists: Pharmacokinetics
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...